SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 351.25 |
| Enterprise Value ($M) | 283.51 |
| Book Value ($M) | 423.50 |
| Book Value / Share | 1.50 |
| Price / Book | 0.83 |
| NCAV ($M) | 229.77 |
| NCAV / Share | 0.81 |
| Price / NCAV | 1.53 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.34 |
| Return on Assets (ROA) | -0.44 |
| Return on Equity (ROE) | -0.56 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 9.84 |
| Current Ratio | 9.84 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 308.79 |
| Assets | 502.53 |
| Liabilities | 79.03 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -157.09 |
| Net Income | -161.65 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -109.42 |
| Cash from Investing | -156.62 |
| Cash from Financing | 240.70 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Suvretta Capital Management, Llc | 4.40 | -10.55 | |
| 13G/A | Novartis Pharma Ag | 4.40 | 0.00 | |
| 13G | T. Rowe Price Investment Management, Inc. | 6.00 | ||
| 13G/A | Armistice Capital, Llc | 0.00 | -100.00 | |
| 13G/A | ARCH Venture Fund X, L.P. | |||
| 13G | BlackRock, Inc. | 5.40 | 0.00 | |
| 13G/A | City Hill, LLC | 11.90 | 2.34 | |
| 13G | Venrock Healthcare Capital Partners III, L.P. | 6.50 | ||
| 13G | Frazier Life Sciences Public Fund, L.P. | 5.90 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 503,051 | 1,445,484 | 34.80 | |
| 658,817 | 1,967,901 | 33.48 | |
| 548,336 | 1,625,929 | 33.72 | |
| 759,119 | 1,516,943 | 50.04 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EDIT – Editas Medicine, Inc. | ELVN – Enliven Therapeutics, Inc. |
| ENTA – Enanta Pharmaceuticals, Inc. | EWTX – Edgewise Therapeutics, Inc. |
| EXEL – Exelixis, Inc. |
Financial data and stock pages provided by
Fintel.io